- 01A blood count points to sickle cell disease; only hemoglobin separation names it
Low hemoglobin, high reticulocytes and high LDH and bilirubin show red cells dying early, which fits sickle cell disease and several other conditions, while sickle cell trait leaves every one of those numbers normal. Hemoglobin HPLC or electrophoresis is the test that tells AA from AS from SS and the other types, so it is the only way to know whether you have the disease, carry the trait, or neither.
Sickle cell disease is an inherited blood disorder that needs two altered hemoglobin genes, one from each parent. One altered gene gives sickle cell trait instead, and most carriers have no idea they have it. About 1 in every 365 Black or African American babies in the US is born with sickle cell disease, and about 1 in 13 with sickle cell trait 1. Most people with the disease are diagnosed as babies through newborn screening; most adults meet sickle cell through a test result instead: a carrier result before a pregnancy, an unexplained anemia, or a question about family history.
What sickle cell anemia is
Sickle cell disease comes from a one-letter change in the beta-globin gene (HBB) that produces an altered hemoglobin called hemoglobin S (HbS) 3. Hemoglobin is the protein inside red cells that carries oxygen; normal adult hemoglobin is called HbA. When HbS gives up its oxygen, the molecules stick together into long rods, and the red cell bends into the crescent or sickle shape that names the disease.
How one gene change becomes anemia and pain
Sickle cell disease affects an estimated 100,000 people in the US 1 and about 4.5 million worldwide, with more than 45 million carrying the trait 12. Most live in sub-Saharan Africa, India and the Middle East. The HbS gene became common where malaria was common, because carrying one copy gives some protection against severe malaria 3. Sickle cell disease also runs in Hispanic, South Asian, Middle Eastern and Mediterranean families.
Sickle cell disease is a family of types, named by the two hemoglobin genes a person carries. Sickle cell anemia means two HbS genes, and it is one specific, inherited cause of anemia. The type matters because it predicts severity and which treatments a hematologist offers. In the tables below, HbF is fetal hemoglobin (which does not sickle), and HbA2 is a minor adult hemoglobin, normally 2 to 3.5%, that rises above that when a beta-thalassemia gene is present.
| Type | Genes inherited | How severe it usually is | What hemoglobin testing shows |
|---|---|---|---|
| HbSS (sickle cell anemia) | HbS from both parents | Most severe and most common | Mostly HbS, no HbA |
| HbS/beta-zero thalassemia | HbS plus a beta-thalassemia gene that makes no normal beta-globin | As severe as HbSS | Mostly HbS, no HbA, raised HbA2, small red cells |
| HbSC | HbS plus HbC | Usually milder; eye and bone problems still common | HbS and HbC in roughly equal amounts |
| HbS/beta-plus thalassemia | HbS plus a beta-thalassemia gene that makes some normal beta-globin | Usually milder | More HbS than HbA, raised HbA2 |
| HbAS (sickle cell trait) | HbS plus one normal gene | Carrier, usually no illness | More HbA than HbS (about 35 to 40% HbS) |
What sickle cell anemia feels like
Sickle cell anemia symptoms come in two layers: a steady background from constant red cell breakdown, and sudden episodes when sickled cells block blood flow. Symptoms usually start around 5 to 6 months of age, when the baby's own fetal hemoglobin gives way to adult hemoglobin.
| Day to day | Crises and complications |
|---|---|
| Fatigue and breathlessness on effort, from anemia | Pain crises (vaso-occlusive crises) in bones, chest, back or belly, lasting hours to days |
| Yellow eyes or skin (jaundice) from broken-down red cells | Painful swelling of the hands and feet in babies (dactylitis) |
| Slower growth and later puberty | Serious infections, because the spleen stops working in early childhood |
| Gallstones from extra bilirubin | Acute chest syndrome: chest pain, fever and a new shadow on a chest X-ray |
| Dilute urine and getting up at night to pass it | Stroke and silent brain injury, kidney damage, leg ulcers, eye damage, hip or shoulder bone death (joint pain), priapism (a painful erection that will not go down) |
A sickle cell crisis, the pain crisis doctors call a vaso-occlusive crisis, often has a trigger: cold or a sudden plunge into cold water, dehydration, infection, high altitude, hard exercise without breaks, and stress. Many crises come with no obvious trigger at all.
When sickle cell disease is an emergency
Sickle cell trait: what being a carrier means
Sickle cell trait means one HbS gene and one normal gene. A person with sickle cell trait has about 35 to 40% HbS, a normal blood count, no anemia and no pain crises, and sickle cell trait never turns into sickle cell disease. Rare problems do occur: collapse and severe muscle breakdown during extreme exercise in heat (US college athletes are screened for this reason; see blood tests for athletes), and blood in the urine, which still needs a cause found (urinalysis explained). In a 2014 JAMA analysis of US cohorts, Naik and colleagues linked sickle cell trait to more chronic kidney disease and albumin in the urine 7.
Very high altitude and severe dehydration are other rare settings where trait can cause sickling, so mention it to your doctor before surgery, mountain trips or heavy training in heat. Trait is also linked to a slightly higher risk of blood clots and, very rarely, a kidney cancer called renal medullary carcinoma.
| Sickle cell trait (HbAS) | Sickle cell disease (HbSS and others) | |
|---|---|---|
| Genes | One HbS, one normal | Two altered genes, at least one HbS |
| HbS on HPLC | About 35 to 40% | Usually 50 to 95% |
| Routine blood count | Normal | Anemia, high reticulocytes (young red cells) |
| Symptoms | Usually none | Pain crises, infections, organ damage |
| What it changes | Family planning; caution in extreme heat and exertion; A1C reads low | Lifelong care with a hematology team |
Sickle cell trait also lowers the A1C test, the 3-month blood sugar marker used to screen for diabetes. As our A1C vs fasting glucose comparison puts it, "Anything that changes how long red cells live (anemia, sickle cell trait, blood loss, pregnancy, kidney failure) can skew A1C." At the same glucose levels, A1C read about 0.3 percentage points lower in people with sickle cell trait 4, which can be enough to move a result from prediabetes into the normal range. If you carry trait and your A1C is borderline, ask for a fasting glucose too.
HbA1c may systematically underestimate past glycemia in black patients with sickle cell trait.
CalculatorA1C calculatorConverts A1C to average glucose, but assumes red cells live a normal lifespan: with trait it reads low, and in sickle cell disease it does not apply.Work it out How sickle cell is passed on
Sickle cell anemia is genetic: it is inherited, never caught, and present from birth. It is recessive, which means a child needs an altered gene from each parent. When both parents carry sickle cell trait, each pregnancy has a 25% chance of a child with sickle cell disease, a 50% chance of a child with trait and a 25% chance of neither. The odds reset with every pregnancy.
| Two carriers (AS and AS) | Parent 2 passes A (normal) | Parent 2 passes S |
|---|---|---|
| Parent 1 passes A (normal) | AA: no trait, no disease | AS: sickle cell trait |
| Parent 1 passes S | AS: sickle cell trait | SS: sickle cell disease |
When one parent has sickle cell disease and the other carries the trait, each child has a 50% chance of the disease and a 50% chance of the trait. A partner with beta-thalassemia trait or HbC trait can pass on HbS/beta-thalassemia or HbSC. Couples can have carrier screening before or early in pregnancy, testing of the pregnancy itself (chorionic villus sampling from about 11 weeks, or amniocentesis later), or IVF with embryo testing; the blood tests in pregnancy guide covers where carrier screening sits.
The blood tests: what points to it, what confirms it
As our anemia guide puts it, "Anemia is a finding, not a diagnosis, so a low number starts the search for a cause." In sickle cell disease, routine labs show anemia plus fast red cell breakdown and replacement. That pattern points to a hemolytic anemia, one where red cells are destroyed early, but it cannot tell sickle cell disease from other hemolytic anemias, and sickle cell trait leaves every routine number normal. The table shows the usual steady-state pattern in HbSS; a CBC supplies the first few rows.
| Marker | Typical in sickle cell anemia (HbSS) | Why |
|---|---|---|
| Hemoglobin | Often 6 to 9 g/dL | Red cells die after 10 to 20 days |
| Reticulocytes | High | The marrow pours out young red cells to keep up |
| LDH | High | Released from broken red cells |
| Indirect bilirubin | High, raising total bilirubin | Made from the hemoglobin of broken cells; causes jaundice |
| Haptoglobin | Low or undetectable | Used up mopping free hemoglobin |
| MCV | Normal or high | Higher on hydroxyurea; low hints at co-inherited thalassemia (Mentzer index) |
| WBC and platelets | Often high at baseline | Ongoing inflammation and a spleen that no longer works |
| Nucleated red cells and smear | Nucleated red cells, sickle cells and target cells (cells with a dark center spot) | Very young red cells released early; sickled cells seen directly |
Markers in the sickle cell blood pattern
Hemoglobin HPLC (high-performance liquid chromatography) or electrophoresis is the test that names sickle cell disease. Both separate the hemoglobin types in a blood sample and report each as a percentage. A normal adult result is roughly 95 to 97% HbA, 2 to 3.5% HbA2 and under 1% HbF. Newborns are tested the same way, and every US state screens all newborns 2. DNA testing settles patterns that stay unclear.
| Result pattern | What it usually means |
|---|---|
| HbA with normal HbA2 and HbF, no HbS | Normal (AA) |
| More HbA than HbS (HbS about 35 to 40%) | Sickle cell trait (AS) |
| HbS with some HbF, no HbA, normal-range HbA2 | Sickle cell anemia (SS) |
| HbS, no HbA, HbA2 above 3.5%, small red cells | HbS/beta-zero thalassemia |
| More HbS than HbA, HbA2 above 3.5% | HbS/beta-plus thalassemia |
| HbS and HbC in about equal amounts | HbSC disease |
| Newborn: FS (mostly HbF plus HbS, no HbA) | Sickle cell disease of some type; repeat testing defines which |
| Newborn: FAS | Sickle cell trait |
Which test answers "do I have sickle cell?"
Adults who were screened at birth often never saw the result, and a state newborn screening lab can sometimes find an old record. Testing makes sense with a family history of sickle cell disease or trait, an unexplained hemolytic anemia, before a pregnancy, before surgery if your status is unknown, and for athletes in heavy training. If you do not know your status, ask your clinician for a hemoglobin HPLC or electrophoresis; if you are planning a pregnancy, ask for your partner to be tested too.
Free, no accountRead your blood testHave a blood count or hemoglobin result with low hemoglobin or high reticulocytes? Read every line of it, free.Read my results
Results that read differently with sickle cell disease
Sickle cell disease changes the meaning of several common tests, and a result inside the reference range can still hide a problem.
| Test | Why it misleads in sickle cell disease | What to use or watch |
|---|---|---|
| A1C | Red cells live too briefly to collect sugar for 3 months, so A1C reads falsely low | The American Diabetes Association advises diagnosing diabetes on glucose alone in sickle cell disease 8: fasting glucose, with fructosamine as a check |
| Creatinine and eGFR | Kidneys overfilter and clear extra creatinine, so creatinine runs low and eGFR looks normal while damage builds | Yearly urine albumin/creatinine ratio from age 10 2; see kidney function explained, cystatin C vs creatinine and chronic kidney disease |
| Ferritin | Rises with repeated transfusions (iron overload) and with inflammation | Transferrin saturation and, for overload, liver iron on MRI |
| Bilirubin | High at baseline from red cell breakdown | The change from your own baseline; Gilbert's syndrome is the other common cause of high indirect bilirubin |
| Hemoglobin | Low at baseline, so a single low value says little | A drop of 2 g/dL or more below your steady state |
Most anemia in sickle cell disease comes from red cell breakdown, and iron deficiency is the less common cause. People who have had many transfusions are more likely to carry too much iron, the same organ-loading problem seen in hemochromatosis. As our hemochromatosis guide puts it, "The transferrin saturation sorts a high ferritin, not the ferritin itself", and that matters here because ferritin climbs with both transfusion iron and inflammation. An iron supplement fits only where ferritin and transferrin saturation show iron deficiency (iron studies explained), and that is a decision for the hematology team.
CalculatorTransferrin saturation calculatorWork out transferrin saturation from serum iron and TIBC (total iron-binding capacity), the number that sits beside ferritin when transfusion iron overload is the question.Work it out Treatment: what works now
Sickle cell disease care starts at diagnosis in infancy and is planned by a hematology team. The NHLBI expert panel recommends daily penicillin until age 5 for children with HbSS, yearly transcranial Doppler scans (an ultrasound of brain blood flow) from age 2 to 16 to find children at high stroke risk, and offering hydroxyurea from 9 months of age in HbSS and HbS/beta-zero thalassemia, with or without symptoms 2. Hydroxyurea raises HbF, the fetal hemoglobin that does not sickle, and in the 1995 Multicenter Study of Hydroxyurea it lowered pain crises and cut acute chest syndrome and transfusions 6.
| Option | Who it is for | What it does | Trade-offs |
|---|---|---|---|
| Penicillin and full vaccines | Children with HbSS, from diagnosis | Prevents overwhelming pneumococcal infection 2 | Daily doses through early childhood |
| Transcranial Doppler screening plus transfusion | Children 2 to 16 with HbSS | Regular transfusion cut first strokes by 92% in children with high scan readings 9 | Ongoing transfusions and iron build-up |
| Hydroxyurea | Offered from 9 months in HbSS and HbS/beta-zero; adults with frequent crises | Raises HbF; fewer crises, less chest syndrome, fewer transfusions 6 | Regular blood counts, because it can lower white cells and platelets; it can harm an unborn baby, so pregnancy and contraception are planned with the hematology team |
| Red cell transfusion (simple or exchange) | Stroke prevention, acute chest syndrome, before surgery | Dilutes sickled cells with donor cells | Iron overload and antibodies to donor cells, so blood is matched on more antigens (blood types explained) |
| Stem cell transplant | Mostly children and young adults with a matched sibling donor | Cure in about 9 of 10 3 | Chemotherapy conditioning (strong chemotherapy to clear the marrow first), graft-versus-host disease (donor immune cells attacking the body), infertility |
| Gene therapy: Casgevy (exa-cel), Lyfgenia (lovo-cel) | Age 12 and over with recurrent crises 5 | Edits or adds genes in the person's own stem cells; long-term durability is still being studied | High-dose chemotherapy, months of hospital care, fertility loss risk; Lyfgenia carries a boxed warning (the FDA's strongest safety warning) for blood cancer 5 |
Sickle cell disease is a rare, debilitating and life-threatening blood disorder with significant unmet need.Nicole Verdun, MD, director of the Office of Therapeutic Products, FDA Center for Biologics Evaluation and Research, December 2023 5
Other drugs have had a bumpier path. Crizanlizumab, an infusion to prevent crises, remains available in the US, but its European authorization was revoked in 2023 after the confirmatory STAND trial showed it did not reduce painful crises needing a healthcare visit 13. Pfizer withdrew voxelotor (Oxbryta) from every market in September 2024 after newer clinical data suggested more pain crises and deaths in treated patients 12. L-glutamine (Endari), approved by the FDA in 2017 for people 5 and older 14, is another option a hematologist may discuss.
What to do next
- Low hemoglobin with high reticulocytes, LDH or bilirubin and no diagnosis: ask your clinician whether a hemoglobin HPLC or electrophoresis is needed, and check ferritin before taking any iron.
- Planning a pregnancy and unsure if you carry trait: both partners can have hemoglobin electrophoresis; see the blood tests in pregnancy guide.
- You carry trait and your A1C is borderline: ask for a fasting glucose as well.
- You have sickle cell disease: know your steady-state hemoglobin, keep up urine albumin and eye checks, and ask your hematologist whether hydroxyurea fits you.
Living well with sickle cell disease
- A written pain plan and a fever plan agreed with your hematology team, so an emergency department sees what works for you.
- Plenty of fluids, warm layers, and planning before flights, mountains or cold-water swimming.
- Dilated eye checks every 1 to 2 years and yearly urine albumin checks from age 10 2.
- Vaccines kept up to date, including pneumococcal, meningococcal and yearly flu shots.
- Pregnancy planned with a specialist, because pregnancy carries higher risks for both mother and baby.
Supplements that come up in sickle cell disease
Folate need is real in sickle cell disease because the marrow makes red cells several times faster than usual, and true folate deficiency shows up as large red cells and a low folate level. Vitamin D is often low in people with sickle cell disease; a 25-OH vitamin D test is worth asking about at a routine visit (vitamin D deficiency).
Life expectancy with sickle cell disease is improving but still shorter than average: in the US it is estimated at more than 20 years below the average 1. A 2019 US modelling study by Lubeck and colleagues projected about 54 years for people with sickle cell disease against 76 for matched peers 11, and that estimate predates wider hydroxyurea use and gene therapy. Most children with sickle cell disease in the US now reach adulthood, and some adults live into their 60s and beyond with steady specialist care.
Sickle cell disease is diagnosed and treated by a hematology team. In someone with sickle cell disease, go to an emergency department now for a fever of 38.5C (101.3F) or higher, chest pain or fast breathing, sudden weakness, facial droop, slurred speech or a severe headache, an erection lasting more than 4 hours, sudden paleness with a swelling belly in a child, sudden vision change, or pain that your usual plan does not control. Do not start iron because a report says anemia unless ferritin and transferrin saturation show iron deficiency, and do not start, stop or change hydroxyurea, penicillin, pain medicine or any supplement without your care team.
Citations
- Centers for Disease Control and Prevention. Data and Statistics on Sickle Cell Disease
- Yawn BP et al. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. JAMA 2014;312:1033-1048
- Piel FB, Steinberg MH, Rees DC. Sickle cell disease. New England Journal of Medicine 2017;376:1561-1573
- Lacy ME et al. Association of sickle cell trait with hemoglobin A1c in African Americans. JAMA 2017;317:507-515
- US Food and Drug Administration. FDA approves first gene therapies to treat patients with sickle cell disease. Press release, 8 December 2023
- Charache S et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. New England Journal of Medicine 1995;332:1317-1322
- Naik RP et al. Association of sickle cell trait with chronic kidney disease and albuminuria in African Americans. JAMA 2014;312:2115-2125
- American Diabetes Association Professional Practice Committee. 2. Diagnosis and classification of diabetes: Standards of Care in Diabetes 2025. Diabetes Care 2025;48(Suppl 1):S27-S49
- Adams RJ et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. New England Journal of Medicine 1998;339:5-11
- Dixit R et al. Folate supplementation in people with sickle cell disease. Cochrane Database of Systematic Reviews 2018;3:CD011130
- Lubeck D et al. Estimated life expectancy and income of patients with sickle cell disease compared with those without sickle cell disease. JAMA Network Open 2019;2:e1915374
- Pfizer. Pfizer voluntarily withdraws all lots of sickle cell disease treatment Oxbryta (voxelotor) from worldwide markets. Press release, 25 September 2024
- European Medicines Agency. Revocation of authorisation for sickle cell disease medicine Adakveo. News release, 26 May 2023
- US Food and Drug Administration. FDA approves new treatment for sickle cell disease. Press release, 7 July 2017
Educational context only, not medical advice or a diagnosis. Always discuss your results with a clinician.






